169 related articles for article (PubMed ID: 37803297)
1. Phosphorylation of EZH2 differs HER2-positive breast cancer invasiveness in a site-specific manner.
Yu F; Li L; Zhang M; Sun S
BMC Cancer; 2023 Oct; 23(1):948. PubMed ID: 37803297
[TBL] [Abstract][Full Text] [Related]
2. Subcellular localization of EZH2 phosphorylated at T367 stratifies metaplastic breast carcinoma subtypes.
McMullen ER; Skala SL; Gonzalez ME; Djomehri S; Chandrashekar DS; Varambally S; Kleer CG
Breast Cancer; 2021 Mar; 28(2):496-505. PubMed ID: 33247371
[TBL] [Abstract][Full Text] [Related]
3. EZH2-mediated PP2A inactivation confers resistance to HER2-targeted breast cancer therapy.
Bao Y; Oguz G; Lee WC; Lee PL; Ghosh K; Li J; Wang P; Lobie PE; Ehmsen S; Ditzel HJ; Wong A; Tan EY; Lee SC; Yu Q
Nat Commun; 2020 Nov; 11(1):5878. PubMed ID: 33208750
[TBL] [Abstract][Full Text] [Related]
4. CDK2-mediated site-specific phosphorylation of EZH2 drives and maintains triple-negative breast cancer.
Nie L; Wei Y; Zhang F; Hsu YH; Chan LC; Xia W; Ke B; Zhu C; Deng R; Tang J; Yao J; Chu YY; Zhao X; Han Y; Hou J; Huo L; Ko HW; Lin WC; Yamaguchi H; Hsu JM; Yang Y; Pan DN; Hsu JL; Kleer CG; Davidson NE; Hortobagyi GN; Hung MC
Nat Commun; 2019 Nov; 10(1):5114. PubMed ID: 31704972
[TBL] [Abstract][Full Text] [Related]
5. Correlation of phosphorylated HER2 with clinicopathological characteristics and efficacy of trastuzumab treatment for breast cancer.
Ramić S; Asić K; Balja MP; Paić F; Benković V; Knežević F
Anticancer Res; 2013 Jun; 33(6):2509-15. PubMed ID: 23749902
[TBL] [Abstract][Full Text] [Related]
6. ZMYND8 preferentially binds phosphorylated EZH2 to promote a PRC2-dependent to -independent function switch in hypoxia-inducible factor-activated cancer.
Tang B; Sun R; Wang D; Sheng H; Wei T; Wang L; Zhang J; Ho TH; Yang L; Wei Q; Huang H
Proc Natl Acad Sci U S A; 2021 Feb; 118(8):. PubMed ID: 33593912
[TBL] [Abstract][Full Text] [Related]
7. EZH2 overexpression in different immunophenotypes of breast carcinoma and association with clinicopathologic features.
Guo S; Li X; Rohr J; Wang Y; Ma S; Chen P; Wang Z
Diagn Pathol; 2016 Apr; 11():41. PubMed ID: 27113214
[TBL] [Abstract][Full Text] [Related]
8. Expression of enhancer of zeste homolog 2 correlates with survival outcome in patients with metastatic breast cancer: exploratory study using primary and paired metastatic lesions.
Inari H; Suganuma N; Kawachi K; Yoshida T; Yamanaka T; Nakamura Y; Yoshihara M; Nakayama H; Yamanaka A; Masudo K; Oshima T; Yokose T; Rino Y; Shimizu S; Miyagi Y; Masuda M
BMC Cancer; 2017 Feb; 17(1):160. PubMed ID: 28241804
[TBL] [Abstract][Full Text] [Related]
9. Correlations of
Ma SJ; Liu YM; Zhang YL; Chen MW; Cao W
Biosci Rep; 2018 Feb; 38(1):. PubMed ID: 29089464
[TBL] [Abstract][Full Text] [Related]
10. Relationship between the expression of Notch1 and EZH2 and the prognosis of breast invasive ductal carcinoma.
Zhao L; Zhang QY; Luan X; Huang X; Zhao S; Zhao H
Genet Mol Res; 2016 Mar; 15(1):. PubMed ID: 27050973
[TBL] [Abstract][Full Text] [Related]
11. A Nomogram for Predicting Liver Metastasis of Lymph-Node Positive Luminal B HER2 Negative Subtype Breast Cancer by Analyzing the Clinicopathological Characteristics of Patients with Breast Cancer.
Yue Y; Liang J; Wu Y; Tong W; Li D; Cao X; Wang X
Technol Cancer Res Treat; 2022; 21():15330338221132669. PubMed ID: 36254567
[No Abstract] [Full Text] [Related]
12. The molecular mechanisms and therapeutic potential of EZH2 in breast cancer.
Adibfar S; Elveny M; Kashikova HS; Mikhailova MV; Farhangnia P; Vakili-Samiani S; Tarokhian H; Jadidi-Niaragh F
Life Sci; 2021 Dec; 286():120047. PubMed ID: 34653429
[TBL] [Abstract][Full Text] [Related]
13. Methylation of EZH2 by PRMT1 regulates its stability and promotes breast cancer metastasis.
Li Z; Wang D; Lu J; Huang B; Wang Y; Dong M; Fan D; Li H; Gao Y; Hou P; Li M; Liu H; Pan ZQ; Zheng J; Bai J
Cell Death Differ; 2020 Dec; 27(12):3226-3242. PubMed ID: 32895488
[TBL] [Abstract][Full Text] [Related]
14. Activated Akt signaling pathway in invasive ductal carcinoma of the breast: correlation with HER2 overexpression.
Park SS; Kim SW
Oncol Rep; 2007 Jul; 18(1):139-43. PubMed ID: 17549359
[TBL] [Abstract][Full Text] [Related]
15. Global H3K27 trimethylation and EZH2 abundance in breast tumor subtypes.
Holm K; Grabau D; Lövgren K; Aradottir S; Gruvberger-Saal S; Howlin J; Saal LH; Ethier SP; Bendahl PO; Stål O; Malmström P; Fernö M; Rydén L; Hegardt C; Borg Å; Ringnér M
Mol Oncol; 2012 Oct; 6(5):494-506. PubMed ID: 22766277
[TBL] [Abstract][Full Text] [Related]
16. The degradation of EZH2 mediated by lncRNA ANCR attenuated the invasion and metastasis of breast cancer.
Li Z; Hou P; Fan D; Dong M; Ma M; Li H; Yao R; Li Y; Wang G; Geng P; Mihretab A; Liu D; Zhang Y; Huang B; Lu J
Cell Death Differ; 2017 Jan; 24(1):59-71. PubMed ID: 27716745
[TBL] [Abstract][Full Text] [Related]
17. Mechanisms of resistance and sensitivity to anti-HER2 therapies in HER2+ breast cancer.
de Melo Gagliato D; Jardim DL; Marchesi MS; Hortobagyi GN
Oncotarget; 2016 Sep; 7(39):64431-64446. PubMed ID: 26824988
[TBL] [Abstract][Full Text] [Related]
18. Trastuzumab effects depend on HER2 phosphorylation in HER2-negative breast cancer cell lines.
Burguin A; Furrer D; Ouellette G; Jacob S; Diorio C; Durocher F
PLoS One; 2020; 15(6):e0234991. PubMed ID: 32584853
[TBL] [Abstract][Full Text] [Related]
19. The long non-coding RNA SNHG1 promotes bladder cancer progression by interacting with miR-143-3p and EZH2.
Xiang W; Lyu L; Huang T; Zheng F; Yuan J; Zhang C; Jiang G
J Cell Mol Med; 2020 Oct; 24(20):11858-11873. PubMed ID: 32885590
[TBL] [Abstract][Full Text] [Related]
20. Curcumin inhibits the growth of triple-negative breast cancer cells by silencing EZH2 and restoring DLC1 expression.
Zhou X; Jiao D; Dou M; Zhang W; Lv L; Chen J; Li L; Wang L; Han X
J Cell Mol Med; 2020 Sep; 24(18):10648-10662. PubMed ID: 32725802
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]